Nemolizumab Medicine 09 January 2018 Extended indication Atopic Dermatitis; Prurigo (jeuk) Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Nemolizumab Domain Chronic immune diseases Reason of inclusion Main indication Skin diseases Extended indication Atopic Dermatitis; Prurigo (jeuk) Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Galderma Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Unknown Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a month Dosage per administration 0,1-0,5-2,0 mg/kg References Bron: Ruzicka et al, N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490 Additional remarks Toediening 1 maal per 4 weken Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € < 15,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks Vergelijkbaar met Dupilumab, zal de concurrentie aan moeten gaan wat de prijs nog zou kunnen drukken. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks